+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

AstraZeneca Plc - Enterprise Tech Ecosystem Series

  • PDF Icon

    Company Profile

  • 20 Pages
  • April 2021
  • GlobalData
  • Astrazeneca PLC
  • ID: 5317656
AstraZeneca Plc - Enterprise Tech Ecosystem Series

Summary

AstraZeneca Plc (AstraZeneca) is a developer, manufacturer, and marketer of prescription pharmaceuticals. The company provides drugs for various therapeutic areas, including oncology, cardiovascular, renal, and metabolic disease (CVRM), respiratory, and others.

AstraZeneca is implementing AI technology in order to gain better understanding of diseases, identify new targets for novel medicines, and enable its scientists to discover and develop new medicines.

AstraZeneca Plc (AstraZeneca) is a developer, manufacturer, and marketer of prescription pharmaceuticals. The company provides drugs for various therapeutic areas, including oncology, cardiovascular, renal, and metabolic disease (CVRM), respiratory, and others.

The report provides information and insights into AstraZeneca Plc's tech activities, including -
  • Insights of its digital transformation strategies and digital venture
  • Overview of technology initiatives covering partnerships and innovative solution launch
  • Insights on each technology initiative including technology theme, objective, and benefits
  • Details of estimated ICT budgets and major ICT contracts

Scope
  • AstraZeneca, along with 16 other partners launched Machine Learning Ledger Orchestration for Drug Discovery (MELLODDY), a new research consortium with the objective to leverage machine learning and accelerate drug discovery through a three-year project.
  • AstraZeneca is also a part of the Machine Learning for Pharmaceutical Discovery and Synthesis (MLPDS) consortium with participants from departments of chemistry, chemical engineering, and computer science at Massachusetts Institute of Technology, and 14 biotechnology and pharmaceutical companies.
  • The company continues to build its expertise in data management and analytics by strategic acquisitions and partnerships. AstraZeneca partnered with Talend to leverage its unified data integration suite to collect, govern, transform, and share the data hosted on AWS cloud architecture.

Reasons to Buy
  • Gain insights into AstraZeneca Plc's tech operations.
  • Gain insights into its tech strategies and innovation initiatives.
  • Gain insights into its technology themes under focus.
  • Gain insights into various technology introduction, adoption, and partnership strategies of AstraZeneca Plc.

Table of Contents

  • Overview
  • Digital Transformation Strategy
  • R&D Centers, Innovation Hubs, and Accelerators
  • Technology Focus
  • Technology Initiatives
  • Partnership Network Map
  • ICT Budgets & Contracts
  • Key Executives
  • About the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • MiNA Therapeutics
  • 4D Molecular Therapeutics
  • Procella Therapeutics
  • X-Chem
  • Ethris
  • Genomic Vision
  • SenzaGen
  • Targos
  • Ultivue
  • Guardant Health